Auto1 Group Se AUTO1 GROUP ORD SH.../ DE000A2LQ884 /
| 24/05/2024 18:36:51 | Chg. - | Volume | Bid06:00:04 | Ask06:00:04 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 6.624EUR | - | 3,105 Turnover: 20,485.466 |
-Bid Size: - | -Ask Size: - | 1.21 bill.EUR | - | - |
GlobeNewswire
31/05
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 ...
GlobeNewswire
31/05
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clon...
GlobeNewswire
17/05
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire
14/05
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in ...
GlobeNewswire
24/04
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of ob...
GlobeNewswire
02/04
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the Europe...
GlobeNewswire
14/03
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
GlobeNewswire
12/03
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certificati...
GlobeNewswire
08/02
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire
08/02
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire
22/01
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleuc...
GlobeNewswire
10/12/2023
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annu...
GlobeNewswire
27/11/2023
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for ...
GlobeNewswire
15/11/2023
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) An...
GlobeNewswire
02/11/2023
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) An...
GlobeNewswire
02/11/2023
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
GlobeNewswire
05/09/2023
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia pu...
GlobeNewswire
10/03/2022
Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Pro...
GlobeNewswire
04/11/2021
Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition
GlobeNewswire
03/11/2021
Autolus Therapeutics Reports Third Quarter 2021 Financial Results and Operational Progress
GlobeNewswire
09/09/2021
Flo Announces $50 Million Series B Funding Round; Bringing Company to $800M Valuation
GlobeNewswire
01/09/2021
Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with r...
GlobeNewswire
09/08/2021
Autolus Therapeutics Announces Promising Innovative Medicine (PIM) designation for obe-cel for the t...
GlobeNewswire
05/08/2021
Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress
